U.S. House · 119th Congress · H.R. 9661
Expedited Access to Biosimilars Act
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Nicholas A. LangworthyR-NY-23
- Introduced
- July 14, 2026, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (2)
1 Democrat, 1 Republican. Each member is shown with the party they were counted with on the day they signed on. How we count these
Original cosponsors
- Kim SchrierD-WA-8
Signed on later
- Robert J. WittmanR-VA-1July 21, 2026